Primobolan 100 mg Methenolone Enanthate

Primobolan 100 mg (Methenolone Enanthate) — Swiss Remedies

• Brand: Swiss Remedies
• Category: Injectable AAS · DHT-derived anabolic agent
• Content: 100 mg/ml methenolone enanthate
• Packing: 10 1 ml ampoules (100 mg per ampoule)
• Origin: Switzerland
• Use: Laboratory research and analytical reference only — not for human or veterinary use.

Product Overview

Methenolone enanthate (Primobolan) is a long-acting injectable anabolic-androgenic steroid derived from DHT.

Because it cannot aromatise to estrogen and has a relatively mild androgenic profile, it is widely used in research exploring muscle preservation, nitrogen balance, anti-catabolic dynamics, androgen-receptor activation, and biomarker changes under caloric deficit.

In modern laboratory environments, Primobolan serves as a reference standard for detecting methenolone metabolites, evaluating exposure kinetics, and modelling anabolic effects with reduced estrogenic influence.

Methenolone and its esters are listed on the WADA S1 Prohibited List.

Key Research Highlights

• DHT-derived structure: Non-aromatising backbone ideal for models requiring anabolic signalling without estrogen conversion.
• Long-acting ester: Enanthate ester extends half-life (~10.5 days) and stabilises release in IM depot models.
• Anti-catabolic potential: Explored for lean mass preservation during negative-calorie or muscle-wasting phases.
• Androgen-receptor specificity: Strong AR affinity with mild androgenic signature.
• Anti-doping relevance: Common analyte in AAS detection; metabolite profiling is an area of active research.

Mechanism of Action

• Androgen receptor activation: Methenolone binds AR in muscle and other tissues, enhancing transcription of anabolic genes.
• Positive nitrogen balance: Supports protein synthesis and prevents catabolism under stress conditions.
• Non-estrogenic: No aromatisation protects against estrogen-related confounders in research models.
• Extended kinetics: Enanthate ester provides slower release and longer detection window than short esters.

Potential Research Applications

Lean-mass retention studies during caloric deficit or immobilisation.

Anti-catabolic pathways and muscle-wasting models.

AR-binding and downstream signalling comparisons with other DHT derivatives.

Lipid panel and cardiovascular markers under AAS exposure.

Anti-doping metabolite detection and identification of long-term biomarkers.

Side Effects & Risk Indicators (Class-Based)

• Endocrine suppression: Reduced LH, FSH, and endogenous testosterone; possible temporary infertility.
• Androgenic effects: Acne, oily skin, androgenic alopecia; virilisation risks in females.
• Cardiometabolic risks: Reduced HDL, increased LDL, potential blood-pressure elevation.
• Liver markers: Lower hepatotoxicity than oral DHT analogues, but elevated enzymes possible with prolonged use.
• Psychological changes: Irritability, mood fluctuation, or behavioural changes — class dependent.

Compliance & Anti-Doping Status

Methenolone (Primobolan) is prohibited at all times by the World Anti-Doping Agency (WADA), Section S1 – Anabolic Agents.

It is a controlled substance in many jurisdictions and often requires prescription authorisation.

This product is supplied strictly for research, forensic, and analytical purposes.

It is not a dietary supplement, not a performance enhancer for human use, and not intended for bodybuilding cycles.

Technical Specifications

Intended Use

Research and analytical reference only